Hemoglobin-based blood substitutes and the treatment of sickle cell disease: More harm than help?

Biomolecules

Volumn 7, Issue 1, 2017, Pages

  Alayash, Abdu I ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

Blood substitutes; Heme oxidation; Hemoglobin; Sickle cell disease

Indexed keywords

BLOOD SUBSTITUTE; CARBON MONOXIDE; DIASPIRIN CROSSLINKED HEMOGLOBIN; HEME OXYGENASE; HEMOGLOBIN; HEMOGLOBIN A; HEMOSPAN; HRC 101; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MACROGOL; METHEMOGLOBIN; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; POLYMERIZED HEMOGLOBIN; REACTIVE OXYGEN METABOLITE; SANGUINATE; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG;

DNA METHYLATION; ENZYME ACTIVITY; HUMAN; HYPOXIA; INFLAMMATION; OXIDATION; OXIDATIVE STRESS; OXYGEN AFFINITY; OXYGEN TRANSPORT; PATHOPHYSIOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRESBYTERIAN; PROTEIN EXPRESSION; REVIEW; SICKLE CELL ANEMIA; SIGNAL TRANSDUCTION; SURVIVAL; ANEMIA, SICKLE CELL; CLINICAL TRIAL (TOPIC); DRUG APPROVAL; DRUG EFFECTS;

ANEMIA, SICKLE CELL; BLOOD SUBSTITUTES; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; HUMANS; OXIDATIVE STRESS; SIGNAL TRANSDUCTION;

EID: 85009754849     PISSN: None     EISSN: 2218273X     Source Type: Journal    
DOI: 10.3390/biom7010002     Document Type: Review

References (82)

1. Kim, H.W.; Greenburg, A.G. Artificial oxygen carriers as red blood cell substitutes: A selected review and current status. Artif. Organs 2004, 28, 813-828. [CrossRef] [PubMed]
2. Winslow, R.M. Oxygen: The poison is in the dose. Transfusion 2013, 53, 424-437. [CrossRef] [PubMed]
3. Winslow, R.M. Cell-free oxygen carriers: Scientific foundations, clinical development, and new directions. Biochim. Biophys. Acta 2008, 1784, 1382-1386. [CrossRef] [PubMed]
4. Alayash, A.I. Hemoglobin-based blood substitutes: Oxygen carriers, pressor agents, or oxidants? Nat. Biotechnol. 1999, 17, 545-549. [CrossRef] [PubMed]
5. Alayash, A.I.; Cashon, R.E. Hemoglobin and free radicals: Implications for the development of a safe blood substitute. Mol. Med. Today 1995, 1, 122-127. [CrossRef]
6. Weiskopf, R.B. Hemoglobin-based oxygen carriers: Disclosed history and the way ahead: The relativity of safety. Anesth. Analg. 2014, 119, 758-760. [CrossRef] [PubMed]
7. Alayash, A.I. Setbacks in blood substitutes research and development: A biochemical perspective. Clin. Lab. Med. 2010, 30, 381-389. [CrossRef] [PubMed]
8. Freilich, D.; Pearce, L.B.; Pitman, A.; Greenburg, G.; Berzins, M.; Bebris, L.; Ahlers, S.; McCarron, R.J. HBOC-201 vasoactivity in a phase III clinical trial in orthopedic surgery subjects—Extrapolation of potential risk for acute trauma trials. J. Trauma 2009, 66, 365-376. [CrossRef] [PubMed]
9. Alayash, A.I. Blood substitutes: Why haven’t we been more successful? Trends Biotechnol. 2014, 32, 177-185. [CrossRef] [PubMed]
10. Reeder, B.J. The redox activity of hemoglobins: From physiologic functions to pathologic mechanisms. Antioxid. Redox Signal. 2010, 13, 1087-1123. [CrossRef] [PubMed]
11. Buehler, P.W.; Alayash, A.I. Toxicities of hemoglobin solutions: In search of in vitro and in vivo model systems. Transfusion 2004, 44, 1516-1530. [CrossRef] [PubMed]
12. Alayash, A.I. Oxygen therapeutics: Can we tame haemoglobin? Nat. Rev. Drug Discov. 2004, 3, 152-159. [CrossRef] [PubMed]
13. Nelson, D.; Azari, M.; Brown, R.; Burhop, K.; Bush, S.; Catarello, J.; Chuang, H.; Downing, C.; Estep, T.; Loewen, A. et al. Preparation and characterization of diaspirin cross-linked hemoglobin solutions for preclinical studies. Biomater. Artif. Cells Immobil. Biotechnol. 1992, 20, 423-427. [CrossRef]
14. Sloan, E.P.; Koenigsberg, M.; Weir, W.B.; Clark, J.M.; O’Connor, R.; Olinger, M.; Cydulka, R. Emergency resuscitation of patients enrolled in the US diaspirin cross-linked hemoglobin (DCLHb) Clinical Efficacy Trial. Prehosp. Disaster Med. 2015, 1, 54-61. [CrossRef] [PubMed]
15. Hoffman, S.J.; Looker, D.L.; Roehrich, J.M.; Cozart, P.E.; Durfee, S.L.; Tedesco, J.L.; Stetler, G.L. Expression of fully functional tetrameric human hemoglobin in coli. Proc. Natl. Acad. Sci. USA 1990, 87, 8521-8525. [CrossRef] [PubMed]
16. Sloan, E.P.; Koenigsberg, M.; Clark, J.M.; Weir, W.B.; Philbin, N. Shock index and prediction of traumatic hemorrhagic shock 28-day mortality: Data from the DCLHb resuscitation clinical trials. West J. Emerg. Med. 2014, 7, 795-802. [CrossRef] [PubMed]
17. Washita, Y. Relationship between chemical properties and biological properties of pyridoxalated hemoglobin polyoxyethylene. Biomat. Artif. Cell Immbol. 1992, 20, 299-307.
18. Kinasewitz, G.T.; Privalle, C.T.; Imm, A.; Steingrub, J.S.; Malcynski, J.T.; Balk, R.A.; DeAngelo, J. Multicenter, randomized, placebo-controlled study of the nitric oxide scavenger pyridoxalated hemoglobin polyoxyethylene in distributive shock. Crit. Care Med. 2008, 36, 1999-2007. [CrossRef] [PubMed]
19. Winslow, R.M. MP4, a new nonvasoactive polyethylene glycol-hemoglobin conjugate. Artif. Organs 2004, 9, 800-806. [CrossRef] [PubMed]
20. Olofsson, C.I.; Górecki, A.Z.; Dirksen, R.; Kofranek, I.; Majewski, J.A.; Mazurkiewicz, T.; Jahoda, D.; Fagrell, B.; Keipert, P.E.; Hardiman, Y.J. et al. Study 6084 Clinical Investigators. Evaluation of MP4OX for prevention of perioperative hypotension in patients undergoing primary hip arthroplasty with spinal anesthesia: A randomized, double-blind, multicenter study. Anesthesiology 2011, 114, 1048-1063. [CrossRef] [PubMed]
21. Gould, S.A.; Moore, E.E.; Hoyt, D.B.; Burch, J.M.; Haenel, J.B.; Garcia, J.; DeWoskin, R.; Moss, G.S. The first randomized trial of human polymerized hemoglobin as a blood substitute in acute trauma and emergent surgery. J. Am. Coll. Surg. 1998, 187, 113-122. [CrossRef]
22. Gould, S.A.; Moore, E.E.; Hoyt, D.B.; Ness, P.M.; Norris, E.J.; Carson, J.L.; Hides, G.A.; Freeman, I.H.; DeWoskin, R.; Moss, G.S. The life sustaining capacity of human polymerized hemoglobin when red cells might be unavailable. J. Am. Coll. Surg. 2002, 195, 445-452. [CrossRef]
23. Levy, J.H.; Goodnough, L.T.; Grelich, P.E.; Parr, G.V.; Stewart, R.W.; Gratz, I.; Wahr, J.; Williams, J.; Comunale, M.E.; Doblar, D. et al. Polymerized bovine hemoglobin solution as a replacement for allogeneic red blood cell transfusion after cardiac surgery: Results of a randomized, double-blind trial. J. Thorac. Cardiovasc. Surg. 2002, 124, 35-42. [CrossRef] [PubMed]
24. Sprung, J.; Kindscher, J.D.; Wahr, J.A.; Levy, J.H.; Monk, T.G.; Moritz, M.W.; O’Hara, P.J. The use of bovine hemoglobin glutamer-250 (Hemopure) in surgical patients: Results of a multicenter, randomized, single-blinded trial. Anesth. Analg. 2002, 94, 799-808. [CrossRef] [PubMed]
25. Boykins, R.A.; Buehler, P.W.; Jia, Y.; Venable, R.; Alayash, A.I. O-raffinose crosslinked hemoglobin lacks site-specific chemistry in the central cavity: Structural and functional consequences of α93Cys modification. Proteins 2005, 59, 840-855. [CrossRef] [PubMed]
26. Carmichael, F.J.; Ali, A.C.; Campbell, J.A.; Langlois, S.F.; Biro, G.P.; Willan, A.R.; Pierce, C.H.; Greenburg, A.G. A phase I study of oxidized raffinose cross-linked human hemoglobin. Crit. Care Med. 2000, 28, 2283-2292. [CrossRef] [PubMed]
27. Hill, S.; Gottschalk, L.I.; Grichnik, K. Safety and preliminary efficacy of hemoglobin raffimer for patients undergoing coronary artery bypass surgery. J. Cardiothorac. Vasc. Anesth. 2002, 16, 695-702. [CrossRef] [PubMed]
28. Silverman, T.A.; Weiskopf, R.B. Hemoglobin-based oxygen carriers: Current status and future directions. Transfusion 2009, 49, 2495-2515. [CrossRef] [PubMed]
29. Buehler, P.W.; D’Agnillo, F. Toxicological consequences of extracellular hemoglobin: Biochemical and physiological perspectives. Antioxid Redox Signal. 2010, 2, 275-291. [CrossRef] [PubMed]
30. Buehler, P.W.; Alayash, A.I. All hemoglobin-based oxygen carriers are not created equally. Biochim. Biophys. Acta 2008, 1784, 1378-1381. [CrossRef] [PubMed]
31. Hess, J.R.; MacDonald, V.W.; Brinkley, W.W. Systemic and pulmonary hypertension after resuscitation with cell-free hemoglobin. J. Appl. Physiol. 1993, 74, 1769-1778. [PubMed]
32. Burhop, K.; Gordon, D.; Estep, T. Review of hemoglobin-induced myocardial lesions. Artif Cells Blood Substit. Immobil. Biotechnol. 2004, 32, 353-374. [CrossRef] [PubMed]
33. Rentsendorj, O.; Zhang, X.; Williams, M.C.; Buehler, P.W.; D’Agnillo, F. Transcriptional suppression of renal antioxidant enzyme systems in guinea pigs exposed to polymerized cell-free hemoglobin. Toxics 2016, 4, 6. [CrossRef] [PubMed]
34. Varnado, C.L.; Mollan, T.L.; Birukou, I.; Smith, B.J.; Henderson, D.P.; Olson, J.S. Development of recombinant hemoglobin-based oxygen carriers. Antioxid. Redox Signal. 2013, 18, 2314-2328. [CrossRef] [PubMed]
35. Engoren, E.M.; Habib, R.H.; Zacharias, A.; Schwann, T.A.; Riordan, C.J.; Durham, S.J. Effect of blood transfusion on long-term survival after cardiac operation. Ann. Thorac. Surg. 2002, 74, 1180-1186. [CrossRef]
36. Zhang, R.; Hess, D.T.; Qian, Z.; Hausladen, A.; Fonseca, F.; Chaube, R.; Reynolds, J.D.; Stamler, J.S. Hemoglobin αCys93 is essential for cardiovascular function and integrated response to hypoxia. Proc. Natl. Acad. Sci. USA 2015, 112, 6425-6430. [CrossRef] [PubMed]
37. Kim-Shapiro, D.B.; Gladwin, M.T. Mechanisms of nitrite bioactivation. Nitric Oxide 2014, 38, 58-68. [CrossRef] [PubMed]
38. Moon-Massat, P.; Scultetus, A.; Arnaud, F.; Brown, A.; Haque, A.; Saha, B.; Kim, B.; Sagini, E.; McGwin, G., Jr.; Auker, C. et al. The effect HBOC-201 and sodium nitrite resuscitation after uncontrolled haemorrhagic shock in swine. Injury 2012, 43, 638-647. [CrossRef] [PubMed]
39. Baek, J.H.; Zhang, X.; Williams, M.C.; Hicks, W.; Buehler, P.W.; D’Agnillo, F. Sodium nitrite potentiates renal oxidative stress and injury in hemoglobin exposed guinea pigs. Toxicology 2015, 333, 89-99. [CrossRef] [PubMed]
40. Machado, R.F.; Barst, R.J.; Yovetich, N.A.; Hassell, K.L.; Kato, G.J.; Gordeuk, V.R.; Gibbs, J.S.; Little, J.A.; Schraufnagel, D.E.; Krishnamurti, L. et al. Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity. Blood 2011, 118, 855-864. [CrossRef] [PubMed]
41. Alayash, A.I. Haptoglobin: Old protein with new functions. Clin. Chim. Acta 2011, 412, 493-498. [CrossRef] [PubMed]
42. Schaer, D.J.; Vinchi, F.; Ingoglia, G.; Tolosano, E.; Buehler, P.W. Haptoglobin, hemopexin, and related defense pathways-basic science, clinical perspectives, and drug development. Front. Physiol. 2014, 5, 415. [CrossRef] [PubMed]
43. Boretti, F.S.; Buehler, P.W.; D’Agnillo, F.; Kluge, K.; Glaus, T.; Butt, O.I.; Jia, Y.; Goede, J.; Pereira, C.P.; Maggiorini, M. et al. Sequestration of extracellular hemoglobin within a haptoglobin complex decreases its hypertensive and oxidative effects in dogs and guinea pigs. J. Clin. Investig. 2009, 119, 2271-2280. [CrossRef] [PubMed]
44. Jia, Y.; Wood, F.; Buehler, P.W.; Alayash, A.I. Haptoglobin preferentially binds α but not α subunits cross-linked hemoglobin tetramers with minimal effects on ligand and redox reactions. PLoS ONE 2013, 8, e59841. [CrossRef] [PubMed]
45. Hebbel, R.P. Reconstructing sickle cell disease: A data-based analysis of the “hyperhemolysis paradigm” for pulmonary hypertension from the perspective of evidence-based medicine. Am. J. Hematol. 2011, 86, 123-154. [CrossRef] [PubMed]
46. Schaer, D.J.; Buehler, P.W.; Alayash, A.I.; Belcher, J.D.; Vercellotti, G.M. Hemolysis and free hemoglobin revisited: Exploring hemoglobin and hemin scavengers as a novel class of therapeutic proteins. Blood 2013, 121, 1276-1284. [CrossRef] [PubMed]
47. Belcher, J.D.; Chen, C.; Nguyen, J.; Milbauer, L.; Abdulla, F.; Alayash, A.I.; Smith, A.; Nath, K.A.; Hebbel, R.P.; Vercellotti, G.M. Heme triggers TLR4 signaling leading to endothelial cell activation and vaso-occlusion in murine sickle cell disease. Blood 2014, 123, 377-390. [CrossRef] [PubMed]
48. Kassa, T.; Jana, S.; Strader, M.B.; Meng, F.; Jia, Y.; Wilson, M.T.; Alayash, A.I. Sickle cell cemoglobin in the ferryl state promotes αCys-93 oxidation and mitochondrial dysfunction in epithelial lung cells (E10). J. Biol. Chem. 2015, 290, 27939-27958. [PubMed]
49. Vichinsky, E. Emerging ‘A’ therapies in hemoglobinopathies: Agonists, antagonists, antioxidants, and arginine. Hematol. Am. Soc. Hematol. Educ. Program 2012, 2012, 271-275.
50. Owusu-Ansah, A.; Ihunnah, C.A.; Walker, A.L.; Ofori-Acquah, S.F. Inflammatory targets of therapy in sickle cell disease. Transl. Res. 2016, 167, 281-297. [CrossRef] [PubMed]
51. Ferrone, F.A. Sickle cell disease: Its molecular mechanism and the one drug that treats it. Int. J. Biol. Macromol. 2016, 93, 1168-1173. [CrossRef] [PubMed]
52. Graves, P.E.; Henderson, D.P.; Horstman, M.J.; Solomon, B.J.; Olson, J.S. Enhancing stability and expression of recombinant human hemoglobin in E. coli: Progress in the development of a recombinant HBOC source. Biochim. Biophys. Acta 2008, 1784, 1471-1479. [CrossRef] [PubMed]
53. Araujo, J.A. HO-1 and CO: Fighters vs sickle cell disease? Blood 2013, 122, 2535-2536. [CrossRef] [PubMed]
54. Vandegriff, K.D.; Young, M.A.; Lohman, J.; Bellelli, A.; Samaja, M.; Malavalli, A.; Winslow, R.M. CO-MP4, a polyethylene glycol-conjugated haemoglobin derivative and carbon monoxide carrier that reduces myocardial infarct size in rats. Br. J. Pharmacol. 2008, 154, 1649-1661. [CrossRef] [PubMed]
55. Belcher, J.D.; Young, M.; Chen, C.; Nguyen, J.; Burhop, K.; Tran, P.; Vercellotti, G.M. MP4CO, a pegylated hemoglobin saturated with carbon monoxide, is a modulator of HO-1, inflammation, and vaso-occlusion in transgenic sickle mice. Blood 2013, 122, 2757-2764. [CrossRef] [PubMed]
56. Telen, M.J. Beyond hydroxyurea: New and old drugs in the pipeline for sickle cell disease. Blood 2016, 127, 810-819. [CrossRef] [PubMed]
57. Nho, K.; Glower, D.; Bredehoeft, S.; Shankar, H.; Shorr, R.; Abuchowski, A. PEG-bovine hemoglobin: Safety in a canine dehydrated hypovolemic-hemorrhagic shock model. Biomater. Artif. Cells Immobil. Biotechnol. 1992, 20, 511-524. [CrossRef]
58. Zhang, J.; Cao, S.; Kwansa, H.; Crafa, D.; Kibler, K.K.; Koehler, R.C. Transfusion of hemoglobin-based oxygen carriers in the carboxy state is beneficial during transient focal cerebral ischemia. J. Appl. Physiol. 2012, 113, 1709-1717. [CrossRef] [PubMed]
59. Abuchowski, A. PEGylated Bovine Carboxyhemoglobin (SANGUINATE™): Results of Clinical Safety Testing and Use in Patients. Adv. Exp. Med. Biol. 2016, 876, 461-467. [PubMed]
60. Gonzalez, P.; Hackney, A.C.; Jones, S.; Strayhorn, D.; Hoffman, E.B.; Hughes, G.; Jacobs, E.E.; Orringer, E.P. A phase I/II study of polymerized bovine hemoglobin in adult patients with sickle cell disease not in crisis at the time of study. Investig. Med. 1997, 45, 258-264.
61. Crawford, M.W.; Shichor, T.; Engelhardt, T.; Adamson, G.; Bell, D.; Carmichael, F.J.; Kim, P.C. The novel hemoglobin-based oxygen carrier HRC 101 improves survival in murine sickle cell disease. Anesthesiology 2007, 107, 281-287. [CrossRef] [PubMed]
62. Mollan, T.L.; Alayash, A.I. Redox reactions of hemoglobin: Mechanisms of toxicity and control. Antioxid. Redox Signal. 2013, 18, 2251-2253. [CrossRef] [PubMed]
63. Jia, Y.; Buehler, P.W.; Boykins, R.A.; Venable, R.M.; Alayash, A.I. Structural basis of peroxide-mediated changes in human hemoglobin: A novel oxidative pathway. J. Biol. Chem. 2007, 282, 4894-4907. [CrossRef] [PubMed]
64. Bonaventura, C.; Henkens, R.; Alayash, A.I.; Crumbliss, A.L. Allosteric effects on oxidative and nitrosative reactions of cell-free hemoglobins. IUBMB Life 2007, 59, 498-505. [CrossRef] [PubMed]
65. Bonaventura, C.; Henkens, R.; Alayash, A.I.; Banerjee, S.; Crumbliss, A.L. Molecular controls of the oxygenation and redox reactions of hemoglobin. Antioxid. Redox Signal. 2013, 18, 2298-2313. [CrossRef] [PubMed]
66. Nagababu, E.; Ramasamy, S.; Rifkind, J.M.; Jia, Y.; Alayash, A.I. Site-specific cross-linking of human and bovine hemoglobins differentially alters oxygen binding and redox side reactions producing rhombic heme and heme degradation. Biochemistry 2002, 41, 7407-7415. [CrossRef] [PubMed]
67. D’Agnillo, F.; Chang, T.M. Polyhemoglobin-superoxide dismutase-catalase as a blood substitute with antioxidant properties. Nat. Biotechnol. 1998, 16, 667-671. [CrossRef] [PubMed]
68. Strader, M.B.; Alayash, A.I. Exploring oxidative reactions in hemoglobin variants using mass spectrometry: Lessons for engineering oxidatively stable oxygen therapeutics. Antioxid. Redox Signal. 2016. [CrossRef] [PubMed]
69. Doherty, D.H.; Doyle, M.P.; Curry, S.R.; Vali, R.J.; Fattor, T.J.; Olson, J.S.; Lemon, D.D. Rate of reaction with nitric oxide determines the hypertensive effect of cell-free hemoglobin. Nat. Biotechnol. 1998, 16, 672-676. [CrossRef] [PubMed]
70. Olson, J.S.; Foley, E.W.; Rogge, C.; Tsai, A.L.; Doyle, M.P.; Lemon, D.D. NO scavenging and the hypertensive effect of hemoglobin-based blood substitutes. Free Radic. Biol. Med. 2004, 36, 685-697. [CrossRef] [PubMed]
71. Buehler, P.W.; D’Agnillo, F.; Hoffman, V.; Alayash, A.I. Effects of endogenous ascorbate on oxidation, oxygenation, and toxicokinetics of cell-free modified hemoglobin after exchange transfusion in rat and guinea pig. J. Pharmacol. Exp. Ther. 2007, 323, 49-60. [CrossRef] [PubMed]
72. Manalo, D.J.; Buehler, P.W.; Baek, J.H.; Butt, O.; D’Agnillo, F.; Alayash, A.I. Acellular haemoglobin attenuates hypoxia-inducible factor-1α (HIF-1α) and its target genes in haemodiluted rats. Biochem. J. 2008, 414, 461-469. [CrossRef] [PubMed]
73. Butt, O.I.; Buehler, P.W.; D’Agnillo, F. Differential induction of renal heme oxygenase and ferritin in ascorbate and non-ascorbate producing species transfused with modified cell-free hemoglobin. Antioxid. Redox Signal. 2010, 12, 199-208. [CrossRef] [PubMed]
74. Fitzgerald, M.C.; Chan, J.Y.; Ross, A.W.; Liew, S.M.; Butt, W.W.; Baguley, D.; Salem, H.H.; Russ, M.K.; Deasy, C.; Martin, K.E. et al. A synthetic haemoglobin-based oxygen carrier and the reversal of cardiac hypoxia secondary to severe anaemia following trauma. Med. J. Aust. 2011, 194, 471-473. [PubMed]
75. Hebbel, R.P.; Morgan, W.T.; Eaton, J.W.; Hedlund, B.E. Accelerated autoxidation and heme loss due to instability of sickle hemoglobin. Proc. Natl. Acad. Sci. USA 1988, 85, 237-241. [CrossRef] [PubMed]
76. Hebbel, R.P.; Ney, P.A.; Foker, W. Autoxidation, dehydration, and adhesivity may be related abnormalities of sickle erythrocytes. Am. J. Physiol. 1989, 56, C579-C583.
77. Marva, E.; Hebbel, R.P. Denaturing interaction between sickle hemoglobin and phosphatidylserine liposomes. Blood 1994, 83, 242-249. [PubMed]
78. George, A.; Pushkaran, S.; Konstantinidis, D.G.; Koochaki, S.; Malik, P.; Mohandas, N.; Zheng, Y.; Joiner, C.H.; Kalfa, T.A. Erythrocyte NADPH oxidase activity modulated by Rac GTPases, PKC, and plasma cytokines contributes to oxidative stress in sickle cell disease. Blood 2013, 121, 2099-2109. [CrossRef] [PubMed]
79. Cyrklaff, M.; Sanchez, C.P.; Kilian, N.; Bisseye, C.; Simpore, J.; Frischknecht, F.; Lanzer, M. Hemoglobins S and C interfere with actin remodeling in Plasmodium falciparum-infected erythrocytes. Science 2011, 334, 1283-1286. [CrossRef] [PubMed]
80. Camus, S.M.; De Moraes, J.A.; Bonnin, P.; Abbyad, P.; Le Jeune, S.; Lionnet, F.; Loufrani, L.; Grimaud, L.; Lambry, J.C.; Charue, D. et al. Circulating cell membrane microparticles transfer heme to endothelial cells and trigger vasoocclusions in sickle cell disease. Blood 2015, 125, 3805-3814. [CrossRef] [PubMed]
81. Jana, S.; Meng, F.; Strader, M.B.; Hicks, W.; Kassa, T.; Tarandovskiy, I.; De Paoli, S.; Simak, J.; Miller, J.L.; Mendelsohn, L. et al. Hemoglobin S oxidation promotes plasma-derived microparticle membrane alterations and toxicity. Blood 2016, 128, 856.
82. Yabuki, A.; Matsushita, M.; Malchesky, P.S.; Iwasaki, K.; Iwashita, Y.; Nosé, Y. In vitro evaluation of a pyridoxalated hemoglobin polyoxyethylene conjugates in reversing cell sickling. ASAIO Trans. 1988, 34, 773-777. [PubMed]